OpenRFPCloses Nov 30, 2026, 12:00 PM CT

Department of War Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program

Defense Health Agency (dha) — DEFENSE HEALTH AGENCYSan Antonio, Texas#HT9402-27-Q-9102

These agreements will be used for the Military Health System (MHS) pharmacy benefits program. The P&T Committee will review new drugs for formulary placement based on clinical and cost-effectiveness. A pre-quotation teleconference will be held on November 17, 2026.

On PublicBidSearch: the original bid posting, 9 bid documents and the agency contact (name and email) for this bid.

Open Original Bid Source Pro

Contact

Agency contact for this bidName and email — included with ProPro

Overview

Due
Nov 30, 2026, 12:00 PM CT
Time stated in bid documents
Nov 30, 2026, 12:00 PM Central Time
Submission
email
Documents analyzed
9
Required submission items
4 items · full checklist with Pro

Steps to Bid

  1. 1

    Download Utilization Dataset and NDC Price List from the website listed in Part 2.3.2.

  2. 2

    Complete applicable pages and price appendices for quote(s) submitted.

    For BPA quotes: Appendix 2, pp. 12-18 and UF BPA Appendix. For ADP quotes: Appendix 3, pp. 19-25 and UF ADP Appendix. For all quotes: Appendix 1, p. 10 Manufacturer Quote Submission Checklist.

What you'll need

Submission

Email

NAICS

325412

How to submit

Send all submissions electronically to RFQ POC listed in part 2.3.

Pursuit snapshot

Pro
  • Go / no-go verdict on every requirement
  • 10 watch-outs that disqualify bidders
  • The 4-item required-submittals checklist
Unlock with Pro — $20/mo

Cancel anytime · no card to browse

Project details

The Department of War (DoW) is required by law (10 U.S.C. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ. The following newly approved drugs will be reviewed by the P&T Committee in February 2027: Atebrioz – Skeletal Muscle Relaxants and Combinations – Subclass: NA; Emcitate – Thyroid and Antithyroid Agents – Subclass: NA; Hibsago – Hepatitis B Agents – Subclass: NA; Juvmo – Parkinsons Agents – Subclass: NA; Zegfrovy – Lung Cancer – Subclass: EGFR+ NSCLC. Instructions, important deadlines, and points of contact are in document RFQ HT9402-27-Q-9102. Details are in Part 2.4.

Key dates

Bids due
Nov 30, 2026, 12:00 PM CT

Documents

  • RFQ_HT9402-27-Q-9102_NAD.pdf26 pages
  • Price_List_-_Atebrioz_-_Skeletal_Muscle_Relaxants_and_Combinations_-_NA.xlsx
  • Price_List_-_Emcitate_-_Thyroid_and_Antithyroid_Agents_-_NA.xlsx
  • Price_List_-_Hibsago_-_Hepatitis_B_Agents_-_NA.xlsx
  • Price_List_-_Juvmo_-_Parkinsons_Agents_-_NA.xlsx
  • Price_List_-_Zegfrovy_-_Lung_Cancer_-_EGFR_NSCLC.xlsx
  • FAR_52-225-6-Certificate.pdf1 pages
  • DoD_Formulary_Placement_of_FDA_Newly_Approved_Drugs.pdf1 pages

1 more file

See all documents · Download with Pro

More from this agency

Similar open bids

Closing this week nearby